Stocks
ALX Oncology Holdings Financial Statements (ALXO) |
||||||||||
| ALX Oncology Holdingssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2019 | 18.03.2021 | 28.02.2022 | 09.03.2023 | 07.03.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 4.80 | 1.18 | 0.000 | 0.000 | 0.000 | 2.48 | |||
| Operating Income, bln rub | -19.2 | -43.7 | -83.6 | -127.4 | -170.3 | -175.8 | ||||
| EBITDA, bln rub | ? | -18.8 | -44.1 | -83.5 | -127.4 | -169.4 | -172.2 | |||
| Net profit, bln rub | ? | -19.2 | -45.7 | -83.5 | -123.5 | -160.8 | -166.2 | |||
| OCF, bln rub | ? | -14.2 | -38.3 | -68.1 | -89.2 | -130.4 | -140.5 | |||
| CAPEX, bln rub | ? | 0.353 | 0.031 | 4.92 | 1.43 | 1.27 | 3.34 | |||
| FCF, bln rub | ? | -14.6 | -38.3 | -73.0 | -90.7 | -131.6 | -141.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 19.6 | 43.8 | 83.6 | 127.4 | 169.4 | 175.4 | ||||
| Cost of production, bln rub | 4.36 | 1.08 | 0.736 | 1.47 | 0.836 | 1.14 | ||||
| R&D, bln rub | 16.3 | 29.0 | 60.2 | 98.4 | 141.8 | 148.7 | ||||
| Interest expenses, bln rub | 0.021 | 0.811 | 0.013 | 4.36 | 1.57 | 1.61 | ||||
| Assets, bln rub | 10.7 | 436.1 | 380.2 | 306.5 | 242.6 | 212.7 | ||||
| Net Assets, bln rub | ? | -0.276 | -118.5 | -202.0 | -325.5 | 189.7 | 164.2 | |||
| Debt, bln rub | 5.42 | 0.000 | 0.742 | 10.4 | 17.2 | 16.8 | ||||
| Cash, bln rub | 9.02 | 434.2 | 363.7 | 282.9 | 182.7 | 157.4 | ||||
| Net debt, bln rub | -3.60 | -434.2 | -362.9 | -272.5 | -165.5 | -140.6 | ||||
| Ordinary share price, rub | 86.2 | 21.5 | 11.3 | 14.9 | 7.70 | |||||
| Number of ordinary shares, mln | 36.5 | 39.8 | 40.3 | 40.7 | 43.0 | 50.1 | ||||
| Market cap, bln rub | 0 | 3 435 | 866 | 459 | 640 | 386 | ||||
| EV, bln rub | ? | -4 | 3 000 | 503 | 186 | 475 | 245 | |||
| Book value, bln rub | 0 | -119 | -202 | -325 | 190 | 164 | ||||
| EPS, rub | ? | -0.53 | -1.15 | -2.07 | -3.03 | -3.74 | -3.32 | |||
| FCF/share, rub | -0.40 | -0.96 | -1.81 | -2.23 | -3.06 | -2.82 | ||||
| BV/share, rub | -0.01 | -2.97 | -5.01 | -8.00 | 4.41 | 3.28 | ||||
| EBITDA margin, % | ? | -391.1% | -3 728% | -6 944% | ||||||
| Net margin, % | ? | -401.2% | -3 870% | -6 702% | ||||||
| FCF yield, % | ? | -1.12% | -8.43% | -19.8% | -20.6% | -36.6% | ||||
| ROE, % | ? | 6 972% | 38.6% | 41.3% | 37.9% | -84.8% | -101.2% | |||
| ROA, % | ? | -180.2% | -10.5% | -22.0% | -40.3% | -66.3% | -78.2% | |||
| P/E | ? | 0.00 | -75.1 | -10.4 | -3.71 | -3.98 | -2.32 | |||
| P/FCF | 0.00 | -89.6 | -11.9 | -5.06 | -4.86 | -2.73 | ||||
| P/S | ? | 0.00 | 2 906 | 155.6 | ||||||
| P/BV | ? | 0.00 | -29.0 | -4.29 | -1.41 | 3.37 | 2.35 | |||
| EV/EBITDA | ? | 0.19 | -68.1 | -6.03 | -1.46 | -2.80 | -1.42 | |||
| Debt/EBITDA | 0.19 | 9.85 | 4.35 | 2.14 | 0.98 | 0.82 | ||||
| R&D/CAPEX, % | 4 619% | 93 423% | 1 222% | 6 896% | 11 130% | 4 456% | ||||
| CAPEX/Revenue, % | 7.36% | 2.62% | 134.6% | |||||||
| ALX Oncology Holdings shareholders | ||||||||||
